Endocyte Stockholders Approve Merger Agreement with Novartis AG
December 20, 2018 09:25 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced...
Endocyte Provides Third Quarter 2018 Financial Results and Operational Update
November 07, 2018 16:01 ET
|
Endocyte, Inc.
Entered into agreement and plan of merger with Novartis AG for $2.1Billion WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical...
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
October 18, 2018 01:10 ET
|
Endocyte, Inc.
Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE...
Endocyte to Present at Two Investor Conferences on October 2nd
September 27, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Announces Closing of Public Offering of Common Stock
September 14, 2018 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces Pricing of Public Offering of Common Stock
September 11, 2018 19:53 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock
September 10, 2018 16:15 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)
September 10, 2018 08:00 ET
|
Endocyte, Inc.
Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval A positive assessment on either rPFS or OS is sufficient for full approval rPFS analysis...
Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference
August 29, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018
August 28, 2018 17:04 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...